RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents

Author's Avatar
Sep 16, 2021
  • Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy manufacturing
  • RepliCel signs an Option to License agreement related to a filed US patent application